Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 18, 2025Infectious Disease ReportsOpen Access

State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDavide MarangoniUniversity of FlorenceABAnna BarbieroUniversity of FlorenceMSMichele SpinicciAzienda Ospedaliero-Universitaria Careggi

Discussion

Loading...

Member takes

Implication

Scoping review highlights efficacy and safety of dengue vaccines in various populations, suggesting optimal strategies.

Key Points

  • TAK-003 is recommended for use in adults and children, indicating strong efficacy against dengue-related hospitalization.
  • CYD-TDV revealed moderate efficacy, but increased hospitalization risk was observed in seronegative individuals, necessitating newer vaccines.
  • Current early-stage candidates, like TDEN and DPIV, face challenges such as waning antibody titers, impacting their efficacy in naive populations.
  • Further research is essential to address immunologic challenges in various demographics, including immunocompromised subjects and travelers.

Cite This Study

Marangoni et al. (2025) studied this question.

synapsesocial.com/papers/68d46ccf31b076d99fa6922chttps://doi.org/10.3390/idr17050117
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval between Infections and Study Year2013 · 265 citations
  2. 2Travel medicine providers’ opinions on the dengue vaccine TAK-003 as a travel vaccine and the need for decision-support information and materials before its launch in Japan2025 · 2 citations
  3. 3Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions2019 · 8 citations
  4. 4Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?2015 · 177 citations
  5. 5Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City2021 · 24 citations